 Autoinflammatory multisystem diseases are a group of diseases that are characterized by recurrent episodes of systemic inflammation as well as organ specific inflammation that can involve the skin, eyes, joints, bones, serosal surfaces, inner ear, and brain. The prominent role of IL-1 in the pathogenesis of these disorders has first become evident through the discovery of mutations in CIAS1 causing the cryopyrin-associated periodic syndromes CAPS including the most severe presentation Neonatal Onset Multisystem Inflammatory Disease NOMID. Over the years we identified additional autoinflammatory diseases including DIRA Deficiency of IL-1 Receptor Antagonist, a disease that is caused by mutations in IL1RN. Therapy with anakinra, the IL-1 receptor antagonist, can be life-saving. We also study additional rare diseases not IL-1 mediated including CANDLE chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures caused by mutations in proteasome components, and recently SAVI STING associated vasculopathy with onset in infancy caused by mutations in TMEM173. Many additional autoinflammatory phenotypes have no genetic causes, including autoinflammatory disorders that are not even clinically defined. Clinical conditions including the spectrum CRMO Chronic Recurrent Multifocal Osteomyelitis, Still s disease, and BehSqrRootBetaet s disease BD with possible involvement of IL-1 dysregulation are also of interest.. In this research protocol we seek to comprehensively evaluate affected patients clinically, genetically, immunologically, and endocrinologically. In addition we intend to evaluate longterm outcomes and biomarkers over the time of observations. Eligibility for ongoing and planned treatment protocols will be determined by screening patients in this protocol. We plan to evaluate patients on a consultative basis for other autoinflammatory diseases for possible enrollment into this study. 